A detailed history of Financial Avengers, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Financial Avengers, Inc. holds 130 shares of BMY stock, worth $7,757. This represents 0.0% of its overall portfolio holdings.

Number of Shares
130
Previous 128 1.56%
Holding current value
$7,757
Previous $5,000 20.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 15, 2024

BUY
$39.66 - $51.75 $79 - $103
2 Added 1.56%
130 $6,000
Q2 2024

Aug 13, 2024

BUY
$40.25 - $52.99 $80 - $105
2 Added 1.59%
128 $5,000
Q1 2024

May 10, 2024

BUY
$47.98 - $54.4 $47 - $54
1 Added 0.8%
126 $6,000
Q4 2023

Feb 12, 2024

BUY
$48.48 - $57.85 $96 - $115
2 Added 1.63%
125 $6,000
Q3 2023

Nov 14, 2023

BUY
$57.89 - $64.73 $57 - $64
1 Added 0.82%
123 $7,000
Q2 2023

Aug 04, 2023

BUY
$63.71 - $70.74 $63 - $70
1 Added 0.83%
122 $7,000
Q1 2023

May 12, 2023

BUY
$65.71 - $74.53 $65 - $74
1 Added 0.83%
121 $8,000
Q4 2022

Feb 06, 2023

BUY
$68.48 - $81.09 $68 - $81
1 Added 0.84%
120 $8,000
Q2 2022

Aug 16, 2022

BUY
$72.62 - $79.98 $72 - $79
1 Added 0.85%
119 $9,000
Q1 2022

May 11, 2022

BUY
$61.48 - $73.72 $61 - $73
1 Added 0.85%
118 $9,000
Q4 2021

Feb 08, 2022

BUY
$53.63 - $62.52 $53 - $62
1 Added 0.86%
117 $7,000
Q3 2021

Nov 01, 2021

BUY
$59.17 - $69.31 $59 - $69
1 Added 0.87%
116 $7,000
Q2 2021

Aug 13, 2021

BUY
$61.91 - $67.42 $61 - $67
1 Added 0.88%
115 $8,000
Q1 2021

May 14, 2021

BUY
$59.34 - $66.74 $59 - $66
1 Added 0.88%
114 $7,000
Q4 2020

Feb 05, 2021

BUY
$57.74 - $65.43 $6,524 - $7,393
113 New
113 $7,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $127B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Financial Avengers, Inc. Portfolio

Follow Financial Avengers, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Financial Avengers, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Financial Avengers, Inc. with notifications on news.